W 972 Pill - white round, 8mm
Pill with imprint W 972 is White, Round and has been identified as Famotidine 10 mg. It is supplied by Wockhardt USA.
Famotidine is used in the treatment of Duodenal Ulcer; GERD; Erosive Esophagitis; Cutaneous Mastocytosis; Duodenal Ulcer Prophylaxis and belongs to the drug class H2 antagonists. There is no proven risk in humans during pregnancy. Famotidine 10 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for W 972
Famotidine
- Imprint
- W 972
- Strength
- 10 mg
- Color
- White
- Size
- 8.00 mm
- Shape
- Round
- Availability
- Rx and/or OTC
- Drug Class
- H2 antagonists
- Pregnancy Category
- B - No proven risk in humans
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Wockhardt USA
- National Drug Code (NDC)
- 64679-0972
- Inactive Ingredients
-
microcrystalline cellulose,
corn starch,
low substituted hydroxypropyl cellulose,
magnesium silicate,
magnesium stearate,
hypromellose 2910 (6 mPa.s),
titanium dioxide,
polyethylene glycol 400,
ferric oxide red,
water
Note: Inactive ingredients may vary.
More about famotidine
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (168)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: H2 antagonists
- Breastfeeding
- En español
Patient resources
- Famotidine drug information
- Famotidine Chewable Tablets
- Famotidine Tablets
- Famotidine Injection Solution
- Famotidine Oral Suspension
Other brands
Pepcid, Pepcid AC, Heartburn Relief, Pepcid Oral Suspension, Pepcid AC Chewable Tablets
Professional resources
- Famotidine monograph
- Famotidine Injection (FDA)
- Famotidine Oral Suspension (FDA)
- Famotidine Tablets (FDA)
Other brands
Pepcid, Pepcid Oral Suspension, Acid Controller Maximum Strength, Acid Controller Original Strength, ... +2 more
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
